Abstract: The present invention relates to antibody-drug conjugates (ADCs) wherein a plurality of active agents are conjugated to an antibody through at least one branched linker. The branched linker may comprise a branching unit, and two active agents are coupled to the branching unit through a secondary linker and the branching unit is coupled to the antibody by a primary linker. The active agents may be the same or different. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g., 2-4 branched linkers, which may each be coupled to a different C-terminal cysteine of a heavy or light chain of the antibody. The branched linker may comprise one active agent coupled to the branching unit by a first branch and a second branch that comprises a polyethylene glycol moiety coupled to the branching unit. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g.

Abstract: The present disclosure relates to a plurality of host materials, organic electroluminescent compounds, and organic electroluminescent devices comprising the same. By comprising specific combinations of compounds according to the present disclosure as the plurality of host materials or by comprising a compound according to the present disclosure, it is possible to provide organic electroluminescent devices having improved lifespan characteristics compared to conventional organic electroluminescent devices.

Abstract: The present disclosure relates to a plurality of host materials, an organic electroluminescent compound, and an organic electroluminescent device comprising the same. An organic electroluminescent device having improved driving voltage, luminous efficiency, and/or lifespan properties compared to a conventional organic electroluminescent device can be provided by including the specific combination of compounds according to the present disclosure as a plurality of host materials or by including the compound according to the present disclosure.

Abstract: The present disclosure relates to a plurality of host materials comprising a first host material comprising at least one compound represented by formula 1 and a second host material comprising at least one compound represented by formula 2, and an organic electroluminescent device comprising the same. An organic electroluminescent device having significantly improved lifetime properties is provided by comprising a specific combination of compounds according to the present disclosure as host materials.

Abstract: An electrode assembly for a rechargeable lithium battery and a rechargeable lithium battery including the same are disclosed. The electrode assembly for the rechargeable lithium battery includes: a negative electrode including a current collector; a negative active material layer; an organic-inorganic composite layer integrated with the negative active material layer, the negative active material layer including an organic layer and an inorganic layer; and a positive electrode, the negative active material layer including a first layer physically contacting the current collector, the first layer including a first carbon-based negative active material, and a second layer on the first layer, including a second carbon-based negative active material, wherein a DD value of the first layer is about 30% to about 90% of a DD value of the negative active material layer, and the DD values are defined by Equation 1.

Abstract: The present invention relates to an electrode assembly for a lithium secondary battery and a lithium secondary battery including the same, the electrode assembly comprising: a current collector, a negative electrode comprising a negative electrode active material layer located on the current collector and an organic-inorganic composite layer integrated with the negative electrode active material layer, and a positive electrode, wherein the organic-inorganic composite layer comprises an organic layer and an inorganic layer.

Abstract: The present invention relates to an electrode assembly for a lithium secondary battery, and a lithium secondary battery comprising same, the electrode assembly comprising a current collector, an anode comprising an anode active material layer located on the current collector and a functional layer integrated with the anode active material layer; and a cathode, wherein the functional layer includes at least one inorganic layer and the peel strength of the functional layer is 0.2 N/m or greater.

Abstract: Compounds of Formula (I), racemates, enantiomers, diastereomers thereof or pharmaceutical acceptable salts thereof, or pharmaceutical compositions containing the compounds, racemates, enantiomers, diastereomers thereof are disclosed. These compounds have GPR40 agonist activity and are capable of modulating blood glucose levels and glucose-dependent insulin secretion mechanism, and, thus, exhibit excellent glucose lowering efficacy without the risk of hypoglycemia. These compounds could be used in preventing and/or treating type 2 diabetes through adequate control of blood glucose.

Abstract: An electrode including a current collector; an electrode active material layer on a surface of the current collector and including internal pores; an inner coating layer filled in the internal pores of the electrode active material layer and including an adhesive material; and an outer coating layer disposed on a surface of the electrode active material layer and including an adhesive material. A total weight of the inner coating layer and the outer coating layer per area of one surface of the current collector is about 0.1 g/m2 to about 0.7 g/m2. In addition, the electrode active material layer has a porosity of about 13% to about 16% in a cross section having a depth of about 20 ?m from the surface of the electrode active material layer to the current collector.

Abstract: Disclosed are a negative electrode for a rechargeable lithium battery and a rechargeable lithium battery including the same, the negative electrode including a current collector, a negative active material layer on the current collector, including a silicon-based negative active material, and an adhesive layer on the negative active material layer, wherein the adhesive layer has a thickness of about 5 ?m or less, the adhesive layer has an area of about 50 area % based on the total area of the negative active material layer, and the adhesive layer is positioned in a dot pattern.

Abstract: An electrode assembly and a rechargeable lithium battery including the same are disclosed herein. The electrode assembly includes an electrode and a separator, wherein the electrode includes a current collector, an electrode active material layer on the current collector, and an adhesive layer on the electrode active material layer; and wherein the separator has a larger surface area than the adhesive layer of the electrode; and a surface of the separator opposing the adhesive layer of the electrode is divided into an adhesive region in contact with the adhesive layer of the electrode and an overhang region not in contact with the adhesive layer of the electrode.

Abstract: Compounds of Formula (I), racemates, enantiomers, diastereomers thereof or pharmaceutical acceptable salts thereof, or pharmaceutical compositions containing the compounds, racemates, enantiomers, diastereomers thereof, and a manufacturing method thereof are disclosed. These compounds have GPR40 agonist activity and are capable of modulating blood glucose levels and glucose-dependent insulin secretion mechanism, and, thus, exhibit excellent glucose lowering efficacy without the risk of hypoglycemia. These compounds could be used in preventing and/or treating type 2 diabetes through adequate control of blood glucose.

Abstract: Compounds of Formula (I), racemates, enantiomers, diastereomers thereof or pharmaceutical acceptable salts thereof, or pharmaceutical compositions containing the compounds, racemates, enantiomers, diastereomers thereof are disclosed. These compounds have GPR40 agonist activity and are capable of modulating blood glucose levels and glucose-dependent insulin secretion mechanism, and, thus, exhibit excellent glucose lowering efficacy without the risk of hypoglycemia. These compounds could be used in preventing and/or treating type 2 diabetes through adequate control of blood glucose.

Abstract: An electrode assembly for a rechargeable lithium battery and a rechargeable lithium battery including the same are disclosed. The electrode assembly for the rechargeable lithium battery includes: a negative electrode including a current collector; a negative active material layer; an organic-inorganic composite layer integrated with the negative active material layer, the negative active material layer including an organic layer and an inorganic layer; and a positive electrode, the negative active material layer including a first layer physically contacting the current collector, the first layer including a first carbon-based negative active material, and a second layer on the first layer, including a second carbon-based negative active material, wherein a DD value of the first layer is about 30% to about 90% of a DD value of the negative active material layer, and the DD values are defined by Equation 1.

Abstract: The present invention relates to the compounds according to Formula (I), the racemates, enantiomers, diastereomers thereof or pharmaceutical acceptable salts thereof, or pharmaceutical compositions comprising these, for the treatment or prevention of metabolic disorders. The compounds according to Formula (I) are, as GPR40 agonists, available for oral administration with glucose-dependent insulin secretion mechanism, which exhibit excellent glucose lowering efficacy without the risk of hypoglycemia. Thus, the compounds and/or pharmaceutical compositions comprising the compounds as effective components are useful in treating and/or preventing symptoms of type 2 diabetes through adequate control of blood glucose.

Abstract: The present disclosure relates to an ?-aminoamide derivative compound and a pharmaceutical composition containing the same. According to various embodiments of the present disclosure, provided is a therapeutic agent which can overcome the disadvantages of existing drugs used as a MAO-B inhibitor and, specifically, reversibly inhibits MAO-B through a non-covalent bond so as to alleviate or eliminate the side effects of the existing drugs which exhibit a therapeutic effect by irreversibly acting via a covalent bond with MAO-B. Particularly, a new compound having superior stability and efficacy compared to the existing reversible MAO-B inhibitors may be provided.

Abstract: Disclosed are a negative active material for a rechargeable lithium battery and a rechargeable lithium battery including the same. The negative active material has an N/P ratio, which is a ratio of a maximum capacity per a unit area of a negative active material relative to maximum capacity per a unit area of a positive active material, ranging from about 1.5 to about 2. The negative active material includes a composite particle of silicon (Si) and carbon and crystalline carbon. A content of the Si is about 3 wt % to about 15 wt % based on a total weight of the negative active material.

Abstract: The present disclosure relates to an ?-aminoamide derivative compound and a pharmaceutical composition containing the same. According to various embodiments of the present disclosure, provided is a therapeutic agent which can overcome the disadvantages of existing drugs used as a MAO-B inhibitor and, specifically, reversibly inhibits MAO-B through a non-covalent bond so as to alleviate or eliminate the side effects of the existing drugs which exhibit a therapeutic effect by irreversibly acting via a covalent bond with MAO-B. Particularly, a new compound having superior stability and efficacy compared to the existing reversible MAO-B inhibitors may be provided.

Abstract: The present invention relates to the compounds according to Formula (1), the racemates, enantiomers, diastereomers thereof or pharmaceutical acceptable salts thereof, or pharmaceutical compositions comprising these, for the treatment or prevention of metabolic disorders. The compounds according to Formula (1) are, as GPR40 agonists, available for oral administration with glucose-dependent insulin secretion mechanism, which exhibit excellent glucose lowering efficacy without the risk of hypoglycemia. Thus, the compounds and/or pharmaceutical compositions comprising the compounds as effective components are useful in treating and/or preventing symptoms of type 2 diabetes through adequate control of blood glucose.

Abstract: The present disclosure relates to an ?-aminoamide derivative compound and a pharmaceutical composition containing the same, for treating a neurodegenerative diseases.